Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years

被引：89

作者：

Cufer, Tanja ^{[1
]}

Ovcaricek, Tanja ^{[2
]}

O'Brien, Mary E. R. ^{[3
]}

机构：

[1] Univ Clin Golnik, Med Oncol Unit, Golnik 4204, Slovenia

[2] Univ Clin Ctr Maribor, Maribor 2000, Slovenia

[3] Royal Marsden Hosp, Sutton SM2 5RS, Surrey, England

来源：

EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷 / 06期

关键词：

Non-small cell lung cancer; Advanced disease; New systemic therapies; PHASE-III TRIAL; RECEPTOR TYROSINE KINASE; DOUBLE-BLIND; 1ST-LINE TREATMENT; MAINTENANCE THERAPY; OPEN-LABEL; DOUBLET CHEMOTHERAPY; WEEKLY PACLITAXEL; RANDOMIZED-TRIAL; ELDERLY-PATIENTS;

D O I：

10.1016/j.ejca.2012.11.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using pemetrexed-containing schemas in non-squamous-cell disease. In addition, maintenance chemotherapy appears to be effective in patients achieving clinical benefit by induction therapy. Targeted therapy based on the presence of activating epidermal growth factor receptor (EGFR) activating mutations or EML4-ALK gene rearrangement is becoming standard practice with high median survival rates, up to 30 months. There are still numerous other molecular targeted drugs in development. This review presents the most recent relevant progress in systemic anti-cancer therapy of advanced NSCLC in the past 5 years and delineates today's new treatment options. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：1216 / 1225

页数：10

共 70 条

[21] Ferry D, 2011, 14 WORLD C LUNG CANC
[22] Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
Fidias, Panos M.
Dakhil, Shaker R.
Lyss, Alan P.
Loesch, David M.
Waterhouse, David M.
Bromund, Jane L.
Chen, Ruqin
Hristova-Kazmierski, Maria
Treat, Joseph
Obasaju, Coleman K.
Marciniak, Martin
Gill, John
Schiller, Joan H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 591 - 598
[23] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
Fukuoka, M
Yano, S
Giaccone, G
Tamura, T
Nakagawa, K
Douillard, JY
Nishiwaki, Y
Vansteenkiste, J
Kudoh, S
Rischin, D
Eek, R
Horai, T
Noda, K
Takata, I
Smit, E
Averbuch, S
Macleod, A
Feyereislova, A
Dong, RP
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
[24] A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
Gaafar, Rabab M.
Surmont, Veerle F.
Scagliotti, Giorgio V.
Van Klaveren, Rob J.
Papamichael, Demetris
Welch, John J.
Hasan, Baktiar
Torri, Valter
van Meerbeeck, Jan P.
[J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (15) : 2331 - 2340
[25] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Gatzemeier, Ulrich
Pluzanska, Anna
Szczesna, Aleksandra
Kaukel, Eckhard
Roubec, Jaromir
De Rosa, Flavio
Milanowski, Janusz
Karnicka-Mlodkowski, Hanna
Pesek, Milos
Serwatowski, Piotr
Ramlau, Rodryg
Janaskova, Terezie
Vansteenkiste, Johan
Strausz, Janos
Manikhas, Georgy Moiseevich
Von Pawel, Joachim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1545 - 1552
[26] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
Giaccone, G
Herbst, RS
Manegold, C
Scagliotti, G
Rosell, R
Miller, V
Natale, RB
Schiller, JH
von Pawel, J
Pluzanska, A
Gatzemeier, M
Grous, J
Ochs, JS
Averbuch, SD
Wolf, MK
Rennie, P
Fandi, A
Johnson, DH
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 777 - 784
[27] Comprehensive genomic characterization of squamous cell lung cancers
Hammerman, Peter S.
Lawrence, Michael S.
Voet, Douglas
Jing, Rui
Cibulskis, Kristian
Sivachenko, Andrey
Stojanov, Petar
McKenna, Aaron
Lander, Eric S.
Gabriel, Stacey
Getz, Gad
Sougnez, Carrie
Imielinski, Marcin
Helman, Elena
Hernandez, Bryan
Pho, Nam H.
Meyerson, Matthew
Chu, Andy
Chun, Hye-Jung E.
Mungall, Andrew J.
Pleasance, Erin
Robertson, A. Gordon
Sipahimalani, Payal
Stoll, Dominik
Balasundaram, Miruna
Birol, Inanc
Butterfield, Yaron S. N.
Chuah, Eric
Coope, Robin J. N.
Corbett, Richard
Dhalla, Noreen
Guin, Ranabir
Hirst, Anhe Carrie
Hirst, Martin
Holt, Robert A.
Lee, Darlene
Li, Haiyan I.
Mayo, Michael
Moore, Richard A.
Mungall, Karen
Nip, Ka Ming
Olshen, Adam
Schein, Jacqueline E.
Slobodan, Jared R.
Tam, Angela
Thiessen, Nina
Varhol, Richard
Zeng, Thomas
Zhao, Yongjun
Jones, Steven J. M.
[J]. NATURE, 2012, 489 (7417) : 519 - 525
[28] Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Henry, David H.
Costa, Luis
Goldwasser, Francois
Hirsh, Vera
Hungria, Vania
Prausova, Jana
Scagliotti, Giorgio Vittorio
Sleeboom, Harm
Spencer, Andrew
Vadhan-Raj, Saroj
von Moos, Roger
Willenbacher, Wolfgang
Woll, Penella J.
Wang, Jianming
Jiang, Qi
Jun, Susie
Dansey, Roger
Yeh, Howard
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1125 - 1132
[29] Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
Herbst, RS
Giaccone, G
Schiller, JH
Natale, RB
Miller, V
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 785 - 794
[30] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, RS
Prager, D
Hermann, R
Fehrenbacher, L
Johnson, BE
Sandler, A
Kris, MG
Tran, HT
Klein, P
Li, X
Ramies, D
Johnson, DH
Miller, VA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5892 - 5899

← 1 2 3 4 5 6 7 →